Arestat™ comprises two fundamentally different aspects of
our platform stabilization technology. Both utilize excipients
and buffers approved by the FDA and EMEA in an unconventional
manner to achieve the desired stability.
Both platform technologies are available for licensing for applications involving
therapeutic proteins, vaccines, medical devices and diagnostics.
Improving the dosing cycle of biopharmaceuticals is very much
an agenda item for many drug companies. One route showing great
promise is the delivery of depot injections comprising bio-particles
containing the active drug which is released slowly into the body
from the site of injection. However, depot formulations of biologics
present two important challenges. The first is sterilization. The
second is the stability of the drug at body temperature or 37°C.
Arecor offers solutions to both problems.
Arestat-R™ permits the terminal sterilization of many
biopharmaceuticals and their carrier molecules without degradation
and Arestat-T™ provides for stability of the drug at body
temperature.
A combination of Arestat-R™ and Arestat-T™ can
readily be applied to the development of depot formulations of
recombinant proteins. Efforts are underway to develop depot
formulations of
Human Growth
Hormone and
Human Insulin.